Amneal Pharmaceuticals (AMRX)
(Delayed Data from NSDQ)
$5.87 USD
-0.03 (-0.51%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.88 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum C VGM
Price, Consensus and EPS Surprise
AMRX 5.87 -0.03(-0.51%)
Will AMRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AMRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMRX
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
AMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar?
Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates
Other News for AMRX
EDIT, CLNE and NIU are among after hour movers
Analysts Conflicted on These Healthcare Names: Amneal Pharmaceuticals (AMRX) and Community Health (CYH)
FDA approves Amneal's generic version of OTC Narcan
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
Amneal Pharmaceuticals announces FDA approval for OTC Naloxone HCI